Omixon is a global biotechnology company that commercializes disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS). The Omixon Holotype HLA™ product combines a targeted HLA Assay and the Omixon HLA Twin™ software to deliver the most accurate high-resolution HLA genotyping available. Omixon maintains an active grant-funded research program and assists scientists and clinicians to analyze the most challenging genomic regions including HLA, KIR and ABO.
In preparation for the full commercialization of Holotype HLA, following a very successful Early Access Program (EAP), we are proud to announce recent additions and new partners in our distributors’ team – welcome to our team GenPlus and Biotron Healthcare, …more
Contact us for more informations about our workshops Novele Allele Discovery with HLA Twin genotyping software, featuring the Traffic Light System (TLS) for efficient throughput With 99.8% accuracy in genotyping NGS data, the Omixon Holotype HLA combined assay and software …more